Ainuovirine vs Doravirine/islatravir (Idvynso)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Ainuovirine

Marketed by Jiangsu Aidea Pharmaceutical Group under a licence from Kainos Medicine

Phase 1 in HIVsmall molecule
Weak signal

NCT01348516 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Safety/ Tolerability Evaluation". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: June 2028 · NCT07631897 (registry estimate)

Reported efficacy

Safety/ Tolerability Evaluation (participants will be followed for the duration of hospital stay, 8-10 days for SAD and 14-16 days for MAD): In 80 healthy male volunteers given single or multiple doses (once daily for 7 days) of 75, 150, 300 or 600 mg or placebo, the drug was generally well tolerated with no serious adverse events and showed dose- and time-dependent nonlinear pharmacokinetics across the 75 to 600 mg range.

Result source: NCT01348516

Doravirine/islatravir (Idvynso)

Marketed by Merck & Co.

Approved in HIVsmall molecule
Partial signal

NCT05631093 · Phase 3 · active, not recruiting

Trial 051 randomized 551 virologically suppressed adults with HIV-1 2:1, open-label, to switch to once-daily doravirine/islatravir or stay on their baseline antiretroviral regimen. The primary efficacy endpoint was the proportion with HIV-1 RNA at or above 50 copies/mL at Week 48, tested for non-inferiority with a 4-percentage-point margin. The rate was 1.4% after the switch and 4.9% on baseline therapy (difference -3.58, 95% CI -7.81 to -0.77), so non-inferiority was shown and the primary endpoint was met. The other registered primaries are adverse-event rates. Source: ClinicalTrials.gov posted results and the IDVYNSO US label, section 14.

Next expected readout: May 2029 · NCT04776252 (registry estimate)

Reported efficacy

Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48; Percentage of Participants Who Experience Adverse Events (AEs) Through Week 48; Percentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 48: HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results). (met)

Result source: NCT05630755

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAinuovirineDoravirine/​islatravir (Idvynso)
HIV-1 RNA below 50 copies/mL (week 48)—Not reported—Trial running · NCT05630755
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Trial running · NCT05630755
CD4 count, change (week 48)—Not reported—Trial running · NCT05630755

HIV-1 RNA below 50 copies/mL (week 48)

Ainuovirine
—Not reported
Doravirine/​islatravir (Idvynso)
—Trial running · NCT05630755

HIV-1 RNA 50 copies/mL or more (week 48)

Ainuovirine
—Not reported
Doravirine/​islatravir (Idvynso)
—Trial running · NCT05630755

CD4 count, change (week 48)

Ainuovirine
—Not reported
Doravirine/​islatravir (Idvynso)
—Trial running · NCT05630755
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Ainuovirine: no structured comparison results are available for HIV.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Doravirine/islatravir (Idvynso)
Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 (Week 48): Group 1: DOR/ISL 88.9% vs Group 2: BIC/FTC/TAF 88.3% NCT04233879 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=366) vs staying on baseline ART (n=185): 1.4% vs 4.9%; difference -3.58 percentage points (95% CI -7.81 to -0.77), non-inferiority p < 0.001 against a 4-point margin (CT.gov posted results). NCT05631093 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results). NCT05630755 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48 (Week 48): Group 1: Doravirine/Islatravir (DOR/ISL) 0% vs Group 2: Baseline Antiretroviral Therapy (ART) 1.5% NCT04223778 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Week 48 HIV-1 RNA ≥50 copies/mL: 0.6% DOR/ISL vs 0.3% BIC/FTC/TAF; treatment difference 0.31 percentage points (95% CI -1.19 to 1.96; p<.001); prespecified non-inferiority margin was 4 percentage points. NCT04223791 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ainuovirine's landscape · Doravirine/islatravir (Idvynso)'s landscape